Background: Status of tumor receptor, including estrogen receptor(ER), progesterone receptor(PR) and Erb-B2 Receptor Tyrosine Kinase 2(ERBB2), is important to predict clinical behavior in breast cancer. Cutaneous metastasis from cancer a dismal sign. However, whether the receptor status would differ primary skin metastatic sites conversion affect remain unknown. Methods: From 2002 2021, 41 pati...

Abstract Background Breast cancer subtypes are known to have different metastatic recurrence sites. Distant metastases often observed during the post-operative course in patients with human epidermal growth factor receptor 2 (HER2)-enriched breast and triple-negative cancer, but relatively rare those hormone receptor-positive HER2-negative (HR+/HER2−) cancer. Tumor-infiltrating lymphocytes (TIL...

BACKGROUND Hormone receptors, including the estrogen receptor and progesterone receptor, human epidermal growth factor receptor 2 (HER2), and other biomarkers like Ki67, epidermal growth factor receptor (EGFR, also known as HER1), the androgen receptor, and p53, are key molecules in breast cancer. This study evaluated the relationship between HER2 and hormone receptors and explored the addition...

The prognosis of hormone receptor (HR)-positive early breast cancer (eBC) may vary according to different factors. Human Epidermal Growth Factor Receptor-2 (HER2) is one them. HER2-low population, defined as HER2 1+ or 2+ with negative fluorescent in situ hybridization (FISH), seems have a than the HER2-0. We aimed explore impact HER2-negative status on risk recurrence PAM50 score. conducted re...

To access possible relationships between breast cancer subtypes (BCS) and patterns of distant metastasis in advanced breast cancer. Breast cancer patients with distant metastasis at two academic centers from 2000-2015 were retrospectively reviewed. The breast cancer was classified into four subtypes: hormone receptor (HR) +/ human epidermal growth factor receptor 2 (HER2) - (i.e., estrogen rece...

In this study, we synthesized Herceptin conjugated magnetic nanoparticles (HMNs) as an alternative probe to discover the levels of HER2 (Human epidermal growth factor receptor-2) in the surface of cells. These nanoparticles can be used by magnetic resonance imaging (MRI) (non-invasive methods) for screening the patients with HER2 positive or negative tumors. Dextran coated iron oxide nanopartic...

ABSTRACT Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand PARPi being investigated breast cancer subtypes. Currently, except for BRCA1/2 mutation carriers with human epidermal growth factor receptor 2 (HER2)-negative cancer, there is inadequate identification of predictive biomarker...

Abstract Objectives We compared the clinicopathologic features, clinical management, and outcomes of human epidermal growth factor receptor 2 (HER2)–expressing nonexpressing microinvasive breast carcinomas (MiBC) to explore significance HER2 in MiBC. Methods Clinicopathologic follow-up information cases with final diagnosis MiBC known status between 2007 2019 were analyzed. Results Nineteen (41...

background: wilms' tumor is an emberyonal tumor arising from remnants of immature renal tissue. her2/neu is an onco-protein which mediates cellular proliferation, differentiation and survival. methods: in the current study, we analyzed her2/neu expression in 40 wilms' tumors. the clinico-demographic data of 40 patients with wilms' tumor were retrieved. immunohistochemical staining for her2/neu ...

The optical redox ratio (fluorescence intensity of NADH divided by that of FAD), was acquired for a panel of breast cancer cell lines to investigate how overexpression of human epidermal growth factor receptor 2 (HER2) affects tumor cell metabolism, and how tumor metabolism may be altered in response to clinically used HER2-targeted therapies. Confocal fluorescence microscopy was used to acquir...